An innovative dry powder inhaler (DPI) designed by product development firm Cambridge Consultants and Chiesi Farmaceutici has been launched onto the market. The patient-friendly NEXThaler® device has been developed for use in the treatment of asthma. Its creative design makes the device very intuitive – all the patient has to do is open it, breathe in, and close it again.
Breathing new life into inhalers
More than 235 million people worldwide suffer from asthma, according to the World Health Organization, and using the right medication correctly can mean the difference between life and death. Although asthma cannot be cured, appropriate management can control the disease and enable people to enjoy a good quality of life.
NEXThaler® has been designed so that when the user opens it, the device automatically provides the correctly measured dose ready for inhalation. All the patient has to do is breathe in – when their air flow reaches the correct rate, the medium-resistance device activates to deliver the extrafine drug particles to both the large and small airways. Closing the device resets the mechanism, and the dose counter lets the patient know how many doses are left. Feedback from both doctors and patients has been positive during user-group international research.
Cambridge Consultants has worked with Chiesi on all aspects of the device – from the creation of the initial design concepts, and detailed device design and development, through device verification testing to working with the manufacturer as the DPI went into production. “Cambridge Consultants represented a ‘one-stop shop’ for all our requirements,” said Paolo Chiesi, vice-president and R&D director at Chiesi. “Its long history of inhaler development meant it was able to come up with solutions to even the most complex problems and enable us to get what is set to be a very successful product onto the market.”
NEXThaler® has been launched this month in Germany and will now be rolled out to the European market – and potentially worldwide. “Our inhaler development expertise means we not only know how to design a device that meets a client’s exacting requirements – but also how to ensure the device is robust when you start to make it in large quantities,” said Dr Matthew Allen, head of drug delivery at Cambridge Consultants.
“Our extensive experience of getting a product to market successfully enabled us to design robustness into the device. We were able to identify potential pitfalls and design solutions to them to ensure that, once the device was on the market, it would work efficiently and consistently. We have worked closely with the manufacturer from pilot production through to proving the robustness of the design during low-volume manufacture and into the scale-up to high-volume production.”
For over 50 years, Cambridge Consultants has led the way in innovative product development. We are the development partner of choice to many of the world’s leading blue chips, as well as the virtual development team for ambitious start-up companies.